Cargando…

Hypertransfusion Therapy in Sickle Cell Disease in Nigeria

Introduction. Hypertransfusion refers to chronic blood transfusion therapy aimed at ameliorating disease complications in various haemopathies particularly the haemoglobinopathies. In sickle cell disease, hypertransfusion is aimed at maintaining patient's haemoglobin level at 10 to 11 g/dL usin...

Descripción completa

Detalles Bibliográficos
Autores principales: Adewoyin, Ademola Samson, Obieche, Jude Chike
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4142279/
https://www.ncbi.nlm.nih.gov/pubmed/25177350
http://dx.doi.org/10.1155/2014/923593
_version_ 1782331750379159552
author Adewoyin, Ademola Samson
Obieche, Jude Chike
author_facet Adewoyin, Ademola Samson
Obieche, Jude Chike
author_sort Adewoyin, Ademola Samson
collection PubMed
description Introduction. Hypertransfusion refers to chronic blood transfusion therapy aimed at ameliorating disease complications in various haemopathies particularly the haemoglobinopathies. In sickle cell disease, hypertransfusion is aimed at maintaining patient's haemoglobin level at 10 to 11 g/dL using haemoglobin AA blood and its resultant dilutional effect on sickle haemoglobin is sustained by intermittent long-term transfusions. Aim and Objective. This paper highlights hypertransfusion and its privileged position as a secondary measure in prevention and treatment of sickle cell disease, especially in the Nigerian context. Materials and Methods. Relevant literatures were searched on PubMed, Google Scholar and standard texts in haematology and transfusion medicine. Keywords used in the search are hypertransfusion, sickle cell disease, chronic transfusion, and Nigeria. Literatures gathered were reviewed, summarized, and presented in this paper. Result. Immense clinical benefit is associated with hypertransfusion therapy including prevention of stroke and amelioration of severe sickle cell disease especially in transplant ineligible patients. Careful patient selections, appropriate blood component, and prevention of transfusion hazards as well as oversight function of an experienced haematologist are pertinent to a successful hypertransfusion therapy. Conclusion. Improved knowledge of the benefits and practice of hypertransfusion will effectively translate into improved health status even among Nigerian sickle cell disease patients.
format Online
Article
Text
id pubmed-4142279
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-41422792014-08-31 Hypertransfusion Therapy in Sickle Cell Disease in Nigeria Adewoyin, Ademola Samson Obieche, Jude Chike Adv Hematol Review Article Introduction. Hypertransfusion refers to chronic blood transfusion therapy aimed at ameliorating disease complications in various haemopathies particularly the haemoglobinopathies. In sickle cell disease, hypertransfusion is aimed at maintaining patient's haemoglobin level at 10 to 11 g/dL using haemoglobin AA blood and its resultant dilutional effect on sickle haemoglobin is sustained by intermittent long-term transfusions. Aim and Objective. This paper highlights hypertransfusion and its privileged position as a secondary measure in prevention and treatment of sickle cell disease, especially in the Nigerian context. Materials and Methods. Relevant literatures were searched on PubMed, Google Scholar and standard texts in haematology and transfusion medicine. Keywords used in the search are hypertransfusion, sickle cell disease, chronic transfusion, and Nigeria. Literatures gathered were reviewed, summarized, and presented in this paper. Result. Immense clinical benefit is associated with hypertransfusion therapy including prevention of stroke and amelioration of severe sickle cell disease especially in transplant ineligible patients. Careful patient selections, appropriate blood component, and prevention of transfusion hazards as well as oversight function of an experienced haematologist are pertinent to a successful hypertransfusion therapy. Conclusion. Improved knowledge of the benefits and practice of hypertransfusion will effectively translate into improved health status even among Nigerian sickle cell disease patients. Hindawi Publishing Corporation 2014 2014-08-07 /pmc/articles/PMC4142279/ /pubmed/25177350 http://dx.doi.org/10.1155/2014/923593 Text en Copyright © 2014 A. S. Adewoyin and J. C. Obieche. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Adewoyin, Ademola Samson
Obieche, Jude Chike
Hypertransfusion Therapy in Sickle Cell Disease in Nigeria
title Hypertransfusion Therapy in Sickle Cell Disease in Nigeria
title_full Hypertransfusion Therapy in Sickle Cell Disease in Nigeria
title_fullStr Hypertransfusion Therapy in Sickle Cell Disease in Nigeria
title_full_unstemmed Hypertransfusion Therapy in Sickle Cell Disease in Nigeria
title_short Hypertransfusion Therapy in Sickle Cell Disease in Nigeria
title_sort hypertransfusion therapy in sickle cell disease in nigeria
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4142279/
https://www.ncbi.nlm.nih.gov/pubmed/25177350
http://dx.doi.org/10.1155/2014/923593
work_keys_str_mv AT adewoyinademolasamson hypertransfusiontherapyinsicklecelldiseaseinnigeria
AT obiechejudechike hypertransfusiontherapyinsicklecelldiseaseinnigeria